drugset / Trial / NCT00147212
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Phase 2
Completed
50 enrolled
Massachusetts General Hospital
Dana-Farber Cancer Institute · collabPharmaMar · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to find out what effects (good or bad) trabectedin (ET743) has on men with advanced prostate carcinoma.
Timeline
- Start
- 2002-06
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trabectedin | Small molecule | — | Intravenous |